Biodefence & Pandemic Preparedness Therapeutics

CSE: RVV | **OTCQB: RVVTF** | **FRANKFURT: 31R**

INVESTOR PRESENTATION · Q3 2026

82 Richmond Street East, Toronto, ON M5C 1P1 | 1-888-901-0036 | info@revivethera.com

IMPORTANT NOTICE

Forward-Looking Statement

This presentation contains forward-looking information within the meaning of applicable Canadian securities legislation, including statements about Revive's strategy in biodefence and pandemic preparedness; the potential safety, efficacy, utility, government relevance or partnerability of bucillamine; the timing, scope and results of additional DRDC studies; potential funding, licensing, procurement, stockpiling or partnership arrangements; regulatory pathways and designations; intellectual property; and the evaluation of complementary therapeutics.

Such information reflects management's current expectations and is subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. Forward-looking information can often, but not always, be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential” or “continue”, or the negative of these terms.

There can be no assurance that any forward-looking information will prove accurate, and readers are cautioned not to place undue reliance on it. Bucillamine is not approved for biodefence or pandemic-preparedness uses. Revive undertakes no obligation to update forward-looking information except as required by law.

Additional risk factors are described in the Company's filings under its profile on SEDAR+ at www.sedarplus.ca.

Revive at a Glance

One focus. Lead asset — bucillamine — aimed at one market: medical countermeasures (biodefence and pandemic preparedness) for governments and defence agencies.

Positive data. In August 2026, DRDC reported that bucillamine matched N-acetylcysteine (NAC) on the measured brain-receptor endpoint — and, unlike NAC, showed no lung hemorrhage.

A government research partner. Defence Research and Development Canada (DRDC), part of the Department of National Defence, is conducting nerve-agent research at its Suffield Research Centre.

A path to non-dilutive funding. Countermeasure buyers are governments; pathways include funded research, grants, licensing, procurement and stockpile contracts.

One Focus.

Lead asset — bucillamine — aimed at one market: medical countermeasures (biodefence and pandemic preparedness) for governments and defence agencies.

Bucillamine is an oral, thiol-based drug with more than 30 years of human use treating rheumatoid arthritis in Japan and South Korea.

Revive has already taken the molecule through late-stage human trials, including a completed Phase 3 program in COVID-19 — giving the company operational and regulatory experience.

That experience is now being redirected toward a government research partnership: Defence Research and Development Canada (DRDC) is studying bucillamine as a potential treatment for nerve-agent exposure, with the results reported positive in August 2026.

AT A GLANCE

LEAD ASSET

Bucillamine — oral thiol-based compound

HUMAN-USE HISTORY

30+ years (Japan & South Korea)

CLINICAL EXPERIENCE

Phase 3 completed in COVID-19 (700+ subjects)

TARGET MARKET

Government biodefence & pandemic preparedness

Governments Are the Buyer

Medical countermeasures are purchased directly by governments, defence organizations and public-health agencies that want products developed, procured and stockpiled before an emergency — outside typical commercial drug-reimbursement channels. Established programs already fund and buy at scale:

BARDA · Project BioShield

U.S. Biomedical Advanced Research and Development Authority — funds development and stockpiling of medical countermeasures.

DoD CBRN Enterprise

U.S. Department of Defense's chemical, biological, radiological & nuclear medical-countermeasure enterprise.

EU HERA

The European Commission's Health Emergency Preparedness and Response Authority.

Established programs exist to fund, procure and stockpile countermeasures before an emergency occurs — creating potential non-dilutive revenue that doesn't depend on commercial drug pricing.

AUGUST 2026 · KEY CATALYST

First DRDC Nerve-Agent Data: Positive

Defence Research and Development Canada (DRDC) compared bucillamine to N-acetylcysteine (NAC) — the established antioxidant comparator — in a recognized animal model of nerve-agent exposure.

- Bucillamine matched NAC in preserving hippocampal GABA receptor post-synaptic density — a measured brain-protection endpoint.
- No pulmonary hemorrhage in the bucillamine group; hemorrhage was observed in the NAC group.
- No cerebral hemorrhage observed in either treatment group.
- Seizure activity and other clinical signs were similar across all groups.

NEXT UP: DRDC confirmatory studies begin Q4-2026, examining brain injury, oxidative stress, respiratory function and response to standard care.

Why Bucillamine

Scientific rationale

A thiol-based drug with antioxidant, anti-inflammatory and thiol-donating properties — potentially relevant where oxidative stress, inflammation and tissue injury drive the harm.

Human-use history

More than 30 years of clinical use for rheumatoid arthritis in Japan and South Korea. Not approved for biodefence or pandemic-preparedness uses.

Development experience

Revive has already taken bucillamine through late-stage human trials, including a Phase 3 program in COVID-19 — real operational and regulatory experience with the molecule.

Government research base

The DRDC study gives an initial, independently generated research basis for further confirmatory work in a nerve-agent exposure model.

Bucillamine Across Four Indications

PRE-CLINICAL

Nerve-Agent Exposure

DRDC — Suffield Research Centre. Positive initial results; confirmatory studies from Q4-2026.

PHASE 3 COMPLETED

Pandemic Preparedness — Influenza, COVID-19, Emerging Viral Infections

Supported by granted Canadian infectious-disease patent. Further development and clinical review required.

EXPLORATORY

Organophosphate Pesticide Poisoning

Under evaluation — whether nerve-agent findings justify research into related compounds.

DESIGNATION HELD

Ischemia-Reperfusion Injury, Liver Transplantation

FDA Orphan Drug Designation granted Feb-2022. Not a current development priority.

Potential Applications Under Evaluation

LEAD	**Nerve-Agent Exposure**	Bucillamine alongside established treatments — brain injury, oxidative stress, respiratory function, response to standard care.
NEAR-TERM	**Organophosphate Pesticide Poisoning**	Whether nerve-agent findings support research into poisoning from related organophosphate compounds.
NEAR-TERM	**Chemical-Threat Neurological & Respiratory Injury**	Downstream tissue injury following toxic exposure, subject to supporting preclinical evidence.
PANDEMIC	**Influenza, COVID-19, Emerging Viruses**	Supported by the scope of the granted Canadian patent; additional development and regulatory review required.
EXPLORATORY	**Long COVID · Traumatic Brain Injury**	Longer-term opportunities including post-viral conditions and TBI from concussive or explosive forces.

How Value Could Be Created

01

Funded Research

Government studies, grants and contracts can generate data.

02

Co-Development & Licensing

Defence, pharma, biotech and manufacturing partners may bring capability, capital or market access.

03

Procurement & Stockpiling

Qualified countermeasures may be purchased and periodically replenished.

04

International Partnering

Regional licences with allied markets that share biodefence and pandemic-preparedness priorities.

Strategy & Roadmap Forward

1	**Confirm & Prioritize**	Work with DRDC through confirmatory studies and select the indications worth advancing.
2	**Build Government & Regulatory Pathway**	Establish pathways in Canada, the U.S. and allied nations.
3	**Strengthen & Broaden IP**	Expand patent coverage across indications, formulations, dosing and combinations.
4	**Partner for Development & Scale**	Work with organizations holding regulatory, manufacturing or government-contracting capability.
5	**Selectively Add Complementary Therapeutics**	New candidates screened with AI-enabled analysis alongside human judgment.

MILESTONES

What to Watch Next

DONE · AUG 2026

Positive DRDC results reported; biodefence and pandemic-preparedness strategy outlined.

Q4 2026

DRDC confirmatory studies continue — brain injury, oxidative stress, respiratory function, response to standard treatment.

2026–2027

Selection of priority indications and development plans for bucillamine.

ONGOING

Discussions with government, defence, research and strategic organizations on studies, funding, regulatory planning, manufacturing, procurement and stockpiling.

ONGOING

Additional patent filings; evaluation of complementary therapeutics, licensing arrangements and development partnerships.

Patent Portfolio

GRANTED

Use of Bucillamine in the Treatment of Infectious Diseases, Including COVID-19

Canadian Patent No. 3,172,170 — expires March 16, 2041.

UNDER REVIEW

Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent

Pending U.S. and Canadian applications (PCT/CA2024/000008, covering US, Canada, Israel).

Additional patent filings are underway to strengthen and broaden IP across indications, formulations, dosing and combinations.

Leadership & Research Partners

LEADERSHIP

- **Michael Frank** — Chairman & Chief Executive Officer
- **Carmelo Marrelli** — Chief Financial Officer
- **Dr. Kelly McKee, Jr., MD, MPH** — Chief Scientific Officer (Consultant)
- **Dr. Arshi Kizilbash, M.D.** — Medical Advisor (Consultant)
- **Dr. Onesmo Mpanju, PhD** — FDA Regulatory Affairs (Consultant)

BOARD OF DIRECTORS

Michael Frank (Chair) · William Jackson · Joshua Herman · Christian Scovenna · Andrew Lindzon

RESEARCH PARTNERS

DRDC RDDC Canada

Nerve-agent research at the Suffield Research Centre, Department of National Defence.

University of Waterloo

Bucillamine formulation development.

Stock & Capital Snapshot

SHARE PRICE	52-WEEK HIGH	52-WEEK LOW	MARKET CAP
C$0.03	C$0.08	C$0.005	~C$13M

COMMON SHARES	WARRANTS	LISTINGS
435,684,000	63,317,263 *Exercise prices range from C$0.05 to C$0.20.*	RVV · RVVTF · 31R *CSE* *OTCQB* *Frankfurt*

THANK YOU

82 Richmond Street East, Toronto, ON M5C 1P1

1-888-901-0036 | info@revivethera.com | revivethera.com

CSE: RVV **OTCQB: RVVTF** **FRANKFURT: 31R**